ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6085
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,880.37
2.52%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aridis Pharmaceuticals Inc (ARDS)

  7. Aridis Pharmaceuticals Inc (ARDS) Noticias

ARDS

Aridis Pharmaceuticals (ARDS)

Aridis Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARDS
FechaHoraFuenteTítuloSímboloCompañía
13/02/202419:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
16/01/202405:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARDSAridis Pharmaceuticals Inc
15/12/202315:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024NASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202315:15GlobeNewswire Inc.Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
03/11/202305:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARDSAridis Pharmaceuticals Inc
13/09/202320:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARDSAridis Pharmaceuticals Inc
04/08/202315:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ARDSAridis Pharmaceuticals Inc
02/08/202307:17GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2 Million OfferingNASDAQ:ARDSAridis Pharmaceuticals Inc
01/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ARDSAridis Pharmaceuticals Inc
21/07/202305:49Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ARDSAridis Pharmaceuticals Inc
17/07/202315:05GlobeNewswire Inc.Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301NASDAQ:ARDSAridis Pharmaceuticals Inc
12/07/202307:00GlobeNewswire Inc.Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) DesignationNASDAQ:ARDSAridis Pharmaceuticals Inc
23/06/202305:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ARDSAridis Pharmaceuticals Inc
20/06/202307:00GlobeNewswire Inc.Aridis Pharmaceuticals' AR-301 Eligible for Consideration under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD)NASDAQ:ARDSAridis Pharmaceuticals Inc
15/06/202316:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ARDSAridis Pharmaceuticals Inc
09/06/202305:13Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
08/06/202315:05GlobeNewswire Inc.Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
31/05/202307:00GlobeNewswire Inc.Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study DesignNASDAQ:ARDSAridis Pharmaceuticals Inc
25/05/202315:05GlobeNewswire Inc.Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-QNASDAQ:ARDSAridis Pharmaceuticals Inc
26/04/202311:15GlobeNewswire Inc.Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-KNASDAQ:ARDSAridis Pharmaceuticals Inc
31/03/202318:00GlobeNewswire Inc.Aridis Provides Corporate UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
20/03/202315:36Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ARDSAridis Pharmaceuticals Inc
14/03/202308:45GlobeNewswire Inc.Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common StockNASDAQ:ARDSAridis Pharmaceuticals Inc
13/03/202307:00GlobeNewswire Inc.Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis PatientsNASDAQ:ARDSAridis Pharmaceuticals Inc
10/02/202309:26Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ARDSAridis Pharmaceuticals Inc
25/01/202315:05GlobeNewswire Inc.Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)NASDAQ:ARDSAridis Pharmaceuticals Inc
17/01/202315:30GlobeNewswire Inc.New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateNASDAQ:ARDSAridis Pharmaceuticals Inc
28/12/202207:30GlobeNewswire Inc.Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25NASDAQ:ARDSAridis Pharmaceuticals Inc
15/12/202215:34Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:ARDSAridis Pharmaceuticals Inc
12/12/202211:25TipRanksAridis Pharmaceuticals (ARDS) Gets a Buy from H.C. WainwrightNASDAQ:ARDSAridis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARDS

Su Consulta Reciente

USOTC
DPER
Deep Earth Resources (CE)
BIT
UB4QBA
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados